Key Details
Price
$3.50Annual EPS
-$1.91Annual ROE
-50.90%Beta
1.24Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 30, 2020Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Interviews with participating patients from the VenoValve® U.S. Pivotal Trial Webcast replay from with the presenting Primary Investigators Presentation with data from the VenoValve U.S. Pivotal Trial Access the Recap Website Here! IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch of a recap website which highlights the Company's participation at the recently held 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium.
The FDA's approval of VenoValve's PMA has the potential to significantly expand NVNO's portfolio of bioprosthetic solutions.
85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical seeking pre-market authorization (PMA) from the U.S. Food and Drug Administration (FDA) to market and sell the VenoValve in the U.S. Among the data being presented at VEITH are: Eighty five percent (85%) of the subjects in the VenoValve pivotal study that reached the one-year milestone achieved a clinically meaningful benefit of a three (3) or more point improvement in revised Venous Clinical Severity Score (rVCSS).
Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application have been submitted, reviewed and approved by the FDA.
FAQ
- What is the primary business of enVVeno Medical?
- What is the ticker symbol for enVVeno Medical?
- Does enVVeno Medical pay dividends?
- What sector is enVVeno Medical in?
- What industry is enVVeno Medical in?
- What country is enVVeno Medical based in?
- When did enVVeno Medical go public?
- Is enVVeno Medical in the S&P 500?
- Is enVVeno Medical in the NASDAQ 100?
- Is enVVeno Medical in the Dow Jones?
- When was enVVeno Medical's last earnings report?
- When does enVVeno Medical report earnings?
- Should I buy enVVeno Medical stock now?